Fulzerasib is an oral targeted medicine being developed for adult patients with specific molecular alterations who require specialized treatment approaches. Available as 150 mg tablets, it is intended for use according to the prescribed treatment regimen, with dosage and duration determined by the treating physician based on individual patient needs and clinical circumstances.



